--- title: "Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.6% - Here's What Happened" type: "News" locale: "en" url: "https://longbridge.com/en/news/282580053.md" description: "Spyglass Pharma (NASDAQ:SGP) shares rose 8.6% to $22.53 on Monday, with a trading volume of 54,323 shares. Analysts have given the stock a consensus rating of \"Moderate Buy\" with a target price of $45.00. Recent reports include upgrades from Zacks Research and Stifel Nicolaus, with price objectives ranging from $37.00 to $62.00. The company reported earnings of ($5.72) per share, exceeding estimates. Director Ra Capital Management acquired 3.69 million shares, increasing their ownership by 162.10%." datetime: "2026-04-13T18:39:29.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282580053.md) - [en](https://longbridge.com/en/news/282580053.md) - [zh-HK](https://longbridge.com/zh-HK/news/282580053.md) --- # Spyglass Pharma (NASDAQ:SGP) Stock Price Up 8.6% - Here's What Happened Spyglass Pharma, Inc. (NASDAQ:SGP - Get Free Report) shares rose 8.6% on Monday . The stock traded as high as $22.58 and last traded at $22.5330. Approximately 54,323 shares were traded during trading, a decline of 56% from the average daily volume of 124,132 shares. The stock had previously closed at $20.75. Get **Spyglass Pharma** alerts: ## Analyst Upgrades and Downgrades SGP has been the topic of several analyst reports. Zacks Research upgraded Spyglass Pharma to a "hold" rating in a research report on Wednesday, March 4th. Stifel Nicolaus assumed coverage on shares of Spyglass Pharma in a research report on Tuesday, March 3rd. They issued a "buy" rating and a $42.00 price objective on the stock. HC Wainwright assumed coverage on shares of Spyglass Pharma in a research report on Tuesday, March 10th. They issued a "buy" rating and a $37.00 price objective on the stock. Jefferies Financial Group assumed coverage on shares of Spyglass Pharma in a research report on Tuesday, March 3rd. They issued a "buy" rating and a $62.00 price objective on the stock. Finally, Citigroup assumed coverage on shares of Spyglass Pharma in a research report on Tuesday, March 3rd. They issued a "buy" rating and a $42.00 price objective on the stock. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, Spyglass Pharma presently has a consensus rating of "Moderate Buy" and a consensus target price of $45.00. **Get Our Latest Stock Report on SGP** ## Spyglass Pharma Stock Up 15.3% Spyglass Pharma (NASDAQ:SGP - Get Free Report) last posted its quarterly earnings data on Thursday, March 26th. The company reported ($5.72) earnings per share for the quarter, topping the consensus estimate of ($6.61) by $0.89. ## Insider Transactions at Spyglass Pharma In other news, Director Ra Capital Management, L.P. bought 3,690,000 shares of the business's stock in a transaction on Monday, February 9th. The stock was acquired at an average price of $16.00 per share, with a total value of $59,040,000.00. Following the completion of the purchase, the director directly owned 5,966,439 shares in the company, valued at $95,463,024. This represents a 162.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. ## Spyglass Pharma Company Profile (Get Free Report) We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT). ## Featured Stories - Five stocks we like better than Spyglass Pharma _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Spyglass Pharma Right Now? Before you consider Spyglass Pharma, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list. While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SGP.US](https://longbridge.com/en/quote/SGP.US.md) ## Related News & Research - [Liminatus Pharma awaits Nasdaq ruling after saying equity tops $2.5 million threshold](https://longbridge.com/en/news/294342373.md) - [Liminatus Pharma Reports Improved Nasdaq Listing Compliance Status](https://longbridge.com/en/news/294345322.md) - [Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 | AAPG Stock News](https://longbridge.com/en/news/293856532.md) - [James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition](https://longbridge.com/en/news/294085325.md) - [Compounded GLP-1 drugs creating concern among doctors and FDA](https://longbridge.com/en/news/293924807.md)